Search

The article discusses several microdiplomacy strategies by the French military and the American Provincial Reconstruction Team (PRT) to combat the insurgency in Kapisa, Afghanistan. It says that Positive Forces Network draws development projects and security initiatives, with the U.S. counterinsurgency doctrine (COIN) campaign. It cites that community engagement with local leaders supports the Afghan government. Moreover, humanitarian aid and promotion of economic development improve security.

The article focuses on the increasing number of pharmaceutical marketers in the U.S. that are turning to high-quality original photography to make their products stand-out from other competing products. Reports indicate that pharmaceutical companies spent $518 million advertising to doctors in 2005, and another $1.6 billion on magazine ads aimed at consumers. Grey Healthcare Group took a photo-driven approach to a doctor-oriented campaign for Puregon, a fertility treatment by Johnson & Johnson's Organon unit, that ran in medical journals.

The article reports on the importance of sales representatives of drug companies in the U.S. in 2012. It highlights a study conducted by BioPharma Alliance which revealed the value of representatives, samples and co-pay cards as marketing tools of the pharmaceutical industry. Meanwhile, it notes some companies which decided to reconsider their commercial models including GlaxoSmithKline, AstraZeneca PLC, and ZS Associates Inc. INSET: No-See By Choice: the hardcore 4%.

The article focuses on the performance of the pharmaceutical industry in the U.S. in 2010. It highlights the analysis from IMS Health Inc. which revealed an increase in the total sales of branded drugs by 2.3 percent to 307.3 billion dollars. According to Michael Kleinrock, director of research and development at IMS Health, the market for pharmaceutical products grew by 3.5 percent. It outlines the top firms in the industry which include Pfizer Inc., GlaxoSmithKline and Merck & Co. Inc.

The article reports on the decline of direct-to-consumer (DTC) advertising spending for prescription drugs from 4.6 billion dollars in October 2009 to 4.4 billion dollars in October 2010 in the U.S. It outlines the top pharmaceutical companies in DTC advertising including Pfizer Inc., Eli Lilly & Co. and GlaxoSmithKline. It highlights the Lipitor brand from Pfizer in which the company spent 272 million dollars for marketing the drug.

The article discusses the move of Pfizer Inc. to invest on patient support programs in the U.S. It states that working on patient compliance is considered as a big opportunity for drug companies to maximize profits from existing products. It notes Pfizer's implementation of Toviaz support plan, known as Your Way, as part of its marketing efforts to boost adherence of patients to the prescribed treatment.

The article provides information on the marketing devices and diagnostics technological innovations of Zimmer AG for the complicated healthcare system in the U.S. Director Ayaz Malik of Zimmer states that the company has differentiated product, differentiated message and excellent consumer story that corresponds the consumer campaigns. He cites the company's Gender Knee effort with smart professional advertising for benefit of the people.

The article presents an analysis on the spending trends of direct-to-consumer (DTC) prescription drugs advertising in 2009 in the U.S. It notes that advertisers increased their DTC expenses following the stability of consumer advertisement outlays. It cites that 62% of DTC advertisement expenditures was attributed to network television (TV) and national magazines. It states that Pfizer Inc. has topped other companies in terms of DTC spending in 2009.

The article focuses on the impact of the healthcare reform legislation on the pharmaceutical industry in the U.S. It states that on June 19, 2009, PhRMA announced its members' intention to put 80 billion dollars in cost-savings toward the health reform cause over 10 years. According to Coalition for Healthcare Communication chief John Kamp, healthcare reform will deliver 15-30 million new patients, mostly in primary and chronic care.

The article offers developments related to continuing medical education (CME) in the U.S. The sector undergone myriads of changes, including the implementation of policies that emphasizes quality. Despite the decline of industry funding for CME, there are still various companies that supported the scheme, including Sanofi-Aventis. Presented are the other updates in CME.

The article discusses the shift to direct-to-consumer (DTC) advertising by the U.S. pharmaceutical marketers. Due to financial constrain, consumer marketers are now shifting to digital media from search engine optimization and website development to online video and social media. Tammy Smalls, senior director of consumer marketing at AstraZeneca, said that they are shifting to more digital efforts because they see that more customers go online to get information about medicines.

The article discusses how victory of Democratic Party in the U.S. Presidential election will impact the pharmaceutical industry of the country. President-elect Barack Obama seem poised to introduce direct negotiations with drug companies on consumer advertising. House Majority Leader Rahm Emanuel set the tone for the approach to pharma marketing in when he told that they would have to choose between tax deductions for research & development (R&D) spending or consumer advertising.

The article focuses on the status of the U.S. presidential candidates toward healthcare. It is stated that John McCain plan to downsize the Medicare prescription drug benefit and push generics over branded drugs. Barack Obama focuses on needless waste and spiraling costs by increasing competition in the insurance and drug markets. However, according to Mike Tanner, both Obama and McCain are similar when it comes to prescription drugs, and both embraced reimportation.

The article reports on the decline of continuing medical education (CME) in the medical sector in the U.S. in 2008. The future of commercially supported CME is predicted to be flat as most medical education and communication companies (MECCs) struggle to reorganize in order to retain their accreditation. The increased numbers of disincentives and the lack of region of interest (ROI) contributed to the decline of CME support.

The article reports on the trends and figures for direct-to-consumer (DTC) drug advertising in the U.S. Accordingly, DTC is set for a change, as marketers extend their targeted and digital-heavy media plans to sale more products in the market. It notes that the emergence of plush Web site and other technological invention had contributed to the expected changes. Meanwhile, it illustrates the rise of DTC spending in major pharmaceutical companies in 2007.

The article focuses on the economic outlook for the U.S. pharmaceutical industry for 2008. It appears that 2008 will be a challenge for pharmaceutical companies since patents on several key products will expire. It is also believed that the trend of new drugs failing to make it to the market in will continue. Because fewer drugs are being approved at the Food and Drug Administration (FDA), pharmaceutical marketers will have less mass-market brands to promote.

A list of the top 20 pharmaceutical companies in the U.S. is presented. These companies include Pfizer Inc., GlaxoSmithKline and Merck & Co. Inc. It also presents their total market sales for 2006 that reaches $274.87 billion. Data is given for sales of individual top products and their advertisement expenses.

The article focuses on the ten years of direct-to-consumer drug advertising in the U.S. It is believed that drug advertising issues have been controversial. The first consumer print advertisement for a prescription drug appeared in the "Reader's Digest" journal in 1981. Despite confusion from the U.S. Food and Drug Administration regarding the rules on drug advertisement, manufacturers still push through in the late 1980s.

The article reports on developments of the political and legislative aspects of the pharmaceutical industry in the U.S. The main issues revolving around the industry include the penalizing of companies for advertising through deductions, the pre-clearance of advertising, and a moratorium on advertising of new drugs. Other issues discussed by politicians include drug pricing, reimportation, the use of physician data by drug companies and pharmaceutical promotions.

The article examines research on how consumers absorb direct-to-consumer drug advertising in the United States. Merck & Co. Inc. is looking into how consumers read broadcast drug advertisements, with a view toward sharing the information gathered with the Food and Drug Administration and competitors. Meanwhile, the Department of Psychology at Duke University has examined distracting visuals in advertising.

The article discusses on the study commissioned by the Association of Hispanic Advertising Agencies, and conducted by TNS Media Intelligence company that determines the share of media spend allocated for Hispanic Americans in the U.S. It emphasizes that most pharmaceutical companies including Big Pharma company lessened its budget allocation advertising in Hispanic American sector. INSET: Star power translates across Ianguages, cultures..

The article focuses on the effort of U.S. drug companies, led by GlaxoSmithKline, to educate consumers about the costs and benefits of medicines. Themes to be used by the firms in promoting drug prices are: first, how today's miracle drugs finance tomorrow's; second, the risk of developing medicines; and last, how research and development costs drive retail prices. The effort targets local media and governments in key states to raise awareness of access and affordability programs.

Reports on the initiative of drug maker Wyeth Inc. in taking bold steps to realign its sales organization in the U.S. Implementation of a novel strategy; Development of its consumer products sales force; Inclusion of its plan to reduce its primary sales force by eliminating full-time positions and hiring seasoned part-time representative. INSETS: Take one tablet PC, every visit;Off-label: dangerous territory..

Focuses on the plans of the government to replace individual consumer as pharma's biggest customer when the new Medicare Prescription Drug Benefit takes effect in January 2005 in the U.S. Challenges facing the Centers for Medicare and Medicaid Services on the implementation of Medicare Part D; Advantages of the program; Complexity of the prescription drug benefit. INSETS: MEDICARE PART D ENROLLMENT SCHEDULE;Drug makers woo pharmacists, but covet switches over persistence;Marriage made in heaven or shotgun wedding?.

Focuses on the pressures faced by the pharmaceutical companies in the U.S. to advertise to direct-to-consumers (DTC) markets in a more responsible way, conveying risks more clearly and running more disease-awareness advertising. Factors that prompt pharmaceutical companies to rethink how they advertise; Action taken by pharmaceutical marketers to demonstrate with online media and customer relationship management (CRM) programming; Comment of Steve Bodhaine, group president and operating officer of Yankelovich Partners, regarding the emergence of DTC as pharmaceutical companies. INSET: The return on investment of DTC.

The article informs that much of Big Pharma breathed a sigh of relief at the news of U.S. President George W. Bush's re-election. Wall Street signaled its approval with a rally in drug stocks, pushing the Amex Pharmaceutical Index of 15 stocks up 3.4 percent the following morning. But major challenges remain for the industry in Washington, Sure, Bush's victory all but ensures implementation of the U.S. Medicare Modernization Act and kindles hope of a more conciliatory approach by the U.S. Department of Health and Human Services.

This article focuses how pharmaceutical companies can harness the growing clout of physician assistants and nurse practitioners in the U.S. Midlevel practitioners, such as nurse practitioners (NPs) and physician assistants (PAs) are an often misunderstood and under-appreciated segment of healthcare providers. The nation's 50,000 PAs and 115,000 NPs perform a broad range of diagnostic tests and write as many as 10 percent of all scripts in the U.S. without physician handholding. They can also receive and dispense samples in most states. The ranks of these midlevel practitioners are growing, even as the number of physicians shrinks and harried doctors depend on them more and more to pick up the slack.

Focuses on the importance of patient compliance to medications on the pharmaceutical industry in the U.S. Compliance with physician's instructions; Direct marketing do's and don'ts. INSET: DIRECT MARKETING DOS AND DON'TS.

Presents views on the state of medical advertising in the United States. Consolidations and merges among marketing companies; Profit and loss structure in business; Impact of price, product line and drug approval on advertising expenditures of pharmaceutical companies. INSETS: Indies fewer, still feisty;MIXED VIEWS ON THE DTC OUTLOOK.

Discusses continued criticism against direct-to-consumer (DTC) drug advertising, despite evidence that it provides a public health benefit by educating consumers. Ways in which the industry might better deal with such criticisms; Advocacy of balancing scientific data with anecdotes that humanize the issues; Ways in which some advertisements scare people into thinking they have conditions they do not really have.

Focuses on ways to determine the returns on investment from online marketing in the U.S. Importance of Internet in creating a communication route for the pharmacists; Potential of electronic detailing and consolidation of online with offline marketing; Increase in the use of the Web for research.

The article presents an outlook of the Patient Protection and Affordable Care Act (ACA) of U.S. President Barack Obama which is slated to take effect in 2014. The Supreme Court ruled that the government does not have the capability to make the law mandatory and even state governors would not opt in fearing that federal subsidies for the expansion will decline over time. The author notes that the act contains language prohibiting the board from rationing care or limiting benefits.

The article focuses on the development of digital media in the U.S. medical industry. According to comScore Inc., nearly half of all Americans seek health information online in November 2011 using a mobile device. It states that the use of online video conferencing for doctor-patient consultations will grow rapidly in the next few years. Tom Abrams of the U.S. Food and Drug Administration (FDA) adds that drug companies must comply with the FDA guidance governing social media communications.

The article focuses on the achievements of privately German owned company Boehringer Ingelheim (BI) GmbH which has continually produces safe and reliable products. It highlights the move of the company to invest and expand in the U.S. market. Furthermore, the approval given by the Food and Drug Administration (FDA) to Pradaxa, a drug indicated for the prevention of stroke and blood clots, has proven to be a turning point for the company's innovation.

The article presents a vision for the U.S. drug industry in 2012. It is said that the U.S. has been affected by deficit-cutting fever, and increasing healthcare costs are driving non-discretionary spending in the federal budget. Congressional supercommittees were considering several measures including deep cuts to Medicare, eliminating the tax deductibility of pharmaceutical advertising and Part D drug rebates that drug companies say amount to price controls.

The article focuses on the need to attach values when launching social media in the U.S. According to Shwen Gwee, lead for digital strategy and social marketing at Vertex Inc., it is about establishing trust, bringing value to the customers and empowering them. It emphasizes on the adoption of mobile and video which is a critical area for marketers.

The article profiles Novo Nordisk A/S, an international healthcare company awarded as the periodical's Company of the Year 2011 in the U.S.. The 85-year-old Danish firm, headed by chief executive officer (CEO) Lars Rebien Sørensen, has incurred an increasing 24% operating profit from January to September 2010. With its constant focus on diabetes, the company has generated a fast-growing sales figures making it one of the most sought stocks in the pharmaceutical industry.

In this article the author discusses the trend of the U.S. pharmaceutical industry in 2011 amid health care reform and the expirations of patents of drugs from some of the most well-established companies in the industry. He states that the massive patent expiration of branded drugs would total about 25 billion dollars. He adds that some of these drugs with expiring patents are Lipitor from Pfizer, Plavix from Sanofi-Aventis and Bristol-Myers Squibb, and Zyprexa from Eli Lilly.

The article focuses on the use of interactive marketing by drug companies in the U.S. despite intense pressure with marketing budgets. It states that pharmaceutical sector's spending on interactive marketing faces competition with other similar firms. Chris Schroeder, chief executive officer (CEO) of HealthCentral, states that providing something of value to users is the key to application development and interactive marketing.

The article presents a corporate profile of pharmaceutical firm Novartis AG. It mentions that the company is in a well-positioned state despite having lost U.S. patent exclusivity on two major drugs, Diovan and Femara, due to its well-diversified business and a string of many franchises. It affirms that for 2008 and 2009, the firm has received approval for new drugs including Affinitor and Reclast which added to their assets.

The article focuses on the move of pharmaceutical companies to cut down advertising costs in the U.S., which is forcing media planners and buyers to look for other opportunities such as online media. Data from TNS Media Intelligence revealed that overall consumer advertising dipped by 3 percent in 2007. Newspaper, radio and outdoor spending on product advertising were among those experiencing sharp decline.

The article discusses the innovations to be introduced in the market by Merck and Co., an international manufacturer and distributor of pharmaceuticals in the U.S. It was stated that the product innovations would include the firm's staid approach and science-centric focus. Such development came after the firm suffered a large amount of unpaid billings. The company is planning to reduce it global workforce and sell its five manufacturing facilities to lessen the expenses.

The article explores the move by McCann Healthcare Worldwide company to increase its revenue despite the challenges in the pharmaceutical industry in the U.S. The company has made a global reorganization while netting a number of clients and has capped a sweeping global consolidation. In addition, McCann reorganized its medical education business, enhancing organizational platform in medical communications.

Analyzes the implication on the pharmaceutical industry of a possible Democrat-dominated Senate and House and the election of a Democrat president in the United States. Support provided by the industry to Republican candidates; Policies towards the pharmaceutical industry of Democratic presidential candidates, John Kerry, John Edwards and Howard Dean.

Presents supplemental new drug applications for 2004 in the U.S. Various pharmaceutical products seeking for market approval; Indications of each; Developer and manufacturer. INSET: NEW INDICATIONS.

The article focuses on the income tax law of North Carolina and planning for future bonus depreciation deductions for transferring assets in a nonrecognition event. It mentions recordkeeping and planning for yearly taxations and deductions of bonus depreciation by corporations, individuals, partnerships, and S corporations.

The article focuses on the professional advertising and promotion agency, CDM New York Co. which seeks more experimental revenue and unconventional streams for growth of revenues. It mentions that the firm is seeking methods to create a nonlinear growth within the firm and revenue streams beyond billable hours. It also notes on the launched of a quick physician poll and collaborated with other agencies in the U.S.

The article discusses the expansion of Cline Davis & Mann Inc., a medical advertising agency in New York. It states that it added another 100 staff to its 575 existing employees. It notes that the agency's revenues from digital media has increased from 5 percent to 45 percent. It also mentions that it will open an office in San Francisco, California and will service Genentech Inc.

The article reports on the increasing trend for generics in the U.S. pharmaceutical industry in 2009. It notes that this grim trend of genericization as branded drugs accounted for a quarter of dispensed scripts in the country. It predicts that loss of patent protection will compel companies to cut research and development (R&D) spending. Senior analyst Tim Anderson advises investors to understand how huge and highly-profitable products finance the other parts of the organization.